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Abstract
The incidence of breast cancer is continuously increasing worldwide, as
influenced by many factors that act synergistically. In the last decade there was
an increasing interest in the possible viral etiology of human breast cancer. Since
then, many viruses have been associated with this disease (murine mammary
tumor virus, MMTV; Epstein-Barr virus, EBV; and human papillomavirus, HPV).
Recently, BLV has been identified in human breast cancers giving rise to the
hypothesis that it could be one of the causative agents of this condition. BLV is a
retrovirus distributed worldwide that affects cattle, causing lymphosarcoma in a
small proportion of infected animals. Because of its similarity with human
retroviruses like HTLV and HIV, BLV was assumed to also be involved in tumor
emergence. Based on this assumption, studies were focused on the possible role









current knowledge on the subject and some prospective analysis that is required







Breast cancer is a multifactorial disease that affects millions of women worldwide
[1] and its incidence is increasing continuously [2]. Globally, it is the most frequent
cancer in females, and every year, 1.7 million new cases are diagnosed [3]. Breast
cancer is about 100 times less common among men than among women, where men
have a lifetime risk of about 1 in 1000 [4]. In developed countries, breast cancer
ranks in fourth place as the cause of death in women, while in developing countries
it falls to sixth place. [5]. There are several risk factors associated with this
pathology such as exposure to high levels of estrogen (through the use of hormonal
contraceptives or hormone replacement therapy), radiation, age, race, number of
births, and obesity after menopause, among others [6, 7]. Moreover, it is known that
mutations on several genes such as BRCA1/2, TP53, PTEN, STK11, CDH1, confer
a higher risk for developing breast cancer [8].
AQ1
In particular, specific inherited mutations in BCRA1 and 2 genes notably increase
the risk of female breast and ovarian cancer. In a recent large study, it was shown
that 72% of women who inherit a harmful BRCA1 mutation and about 69% of
women who inherit a harmful BRCA2 mutation will develop breast cancer by the
age of 80 [9].
Many viruses have been associated with human cancers and it is believed that
approximately 12% of cancers have a viral etiology [10]. In most cases, viral
infection is necessary, but not enough for the development of the tumor. These
viruses usually have a wide distribution. However, they only cause cancer in a




The possible viral etiology of breast cancer had its onset with the discovery of
MMTV as the causative agent of murine breast cancer. Since then, many viruses
such as EBV, HPV and MMTV-like sequences have been identified in human
mammary tumors [12, 13]. A study in Colombia identified BLV 51kD surface
glycoprotein (gp51) of the viral envelope in histological samples of human breast
cancer by immunohistochemistry [14]. In 2014, researchers from California
detected, for the first time, transcripts of the BLV gene tax in human breast cancer
using in situ PCR in slides obtained from formalin-fixed, paraffin-embedded tissues
(FFPE) [15]. The information presented above raises the hypothesis that BLV could
play a role in the development and/or progression of breast cancer. The aim of this
work is to review the knowledge about the virus and to analyze the latest findings
on the possible relationship of BLV and human breast cancer.
The Virus
BLV belongs to the Retroviridae family and is the causative agent of bovine
enzootic leukemia. This δ-retrovirus is closely related to the human T-lymphotropic
virus type 1 (HTLV-1). The virus’ particles range from 60 to 125 nm, with an
envelope, an icosahedral capsid and diploid positive sense RNA genome. All the
genetic information for completing the viral cycle is flanked by two identical long
terminal repeats (LTRs). Apart from the structural proteins, the virus encodes
regulatory proteins such as Tax, Rex, G4 and G3, and also expresses regulatory
microRNAs [16].
The main target cell in cattle is the IgM /CD5  B-lymphocyte. Nevertheless, it can
also infect other cells such as monocytes, macrophages and T-lymphocytes [17].
Most of the infected animals are asymptomatic and do not suffer alterations in
lymphocyte count. These animals can only be identified as infected by detecting the
presence of anti-BLV antibodies or by measuring the proviral load in blood samples
[18]. Approximately 30% of the infected animals develop persistent lymphocytosis
(PL), a condition characterized by a benign clonal expansion of B-lymphocytes.
Animals with PL usually remain stable for long periods or even for their entire life.
However, by mechanisms still unknown, less than 10% progress to lymphosarcoma,
a terminal phase of the disease [19].
Contact with infected cells is the only means of transmission because free BLV
particles are unstable and they are not efficient in the infection process. The main
route of transmission between animals is iatrogenic mainly by the use of




Vertical transmission occurs in 4 to 18% of the cases and the risk is higher in
animals borne from PL mothers [21]. In an experiment carried out with infected
cows, high proviral loads in colostrum correlated with high proviral loads in blood,
leading to higher risk of transmission [22]. However, other studies support that
maternal antibodies contained in milk and colostrum protect the dam and minimize
transmission by this route [23, 24].
The viral cycle is well known in bovines. After viral recognition through a
membrane receptor, membrane fusion occurs, allowing the liberation of the capsid
into the cytoplasm of the host cell. Viral reverse transcriptase synthesizes a double
strand DNA using the viral RNA as template, with a short DNA-RNA hybrid step.
This molecule of DNA forms a complex with the integrase and other cellular
proteins to introduce the viral genome into the nucleus, which finally integrates into
the host genome. Once integrated, the provirus codifies for nucleic acid and
proteins to assemble new viral particles. These particles are released by exocytosis
to produce new infective virions [25]. Due to viral integration into the host genome,
each cell division originates a new infected cell.
Insertion of BLV nucleic acid frequently occurs in intronic regions. However, there
is no specific site for insertion. It has been described that insertion in these low
transcriptional regions helps to maintain virus latency, allowing for low expression
levels that are enough to stimulate the host immune response [26]. It is believed
that cells that are actively expressing virus are detected by the immune system. On
the other hand, cells that carry provirus in transcriptionally-inactive sites are not
recognized by the immune response. Thus, the infected cells accumulate causing
lymphocytosis or proliferation of B-cells, a condition that characterizes this disease
[27].
Could BLV Infect Humans?
After the discovery of BLV, antibodies against this virus were not detected in
humans. Therefore, the idea of a possible zoonosis was discarded. However, the
development of new and more sensitive diagnostic methods allowed the detection
of antibodies against viral proteins in human sera [28]. These findings were the
starting point in the debate about the possibility of BLV infecting humans. The
presence of these antibodies only implies that humans are exposed to BLV but does
not confirm an infection.
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For an infection to occur there must be a receptor that allows virus to enter the cell.
Transmembrane proteins that internalize different substances are used as receptors
by several members of the Retroviridae family [29]. The closely related virus
HTLV-1 uses the glucose transporter GLUT-1 as a cell receptor [30]. In the case of
BLV, scientists have not yet identified the receptor. It is believed that the receptor is
the δ subunit of bovine adaptor protein complex 3 (AP-3) [31]. Humans have four
types of AP complexes that are widely distributed in the body and have an
important role in intracellular transport [32]. The existence of a human homolog of
bovine BLV receptor means that there is a chance that BLV can infect this species.
In fact, scientists were able to infect human cell lines with the virus in vitro [33].
The exact way by which the virus might be transmitted to humans is still unknown.
It was proposed that unpasteurized milk or undercooked meat could be a way in
which the virus enters the body. It has been reported that the genetic material
corresponding to the viral gene gag is present in fresh milk and raw meat [34].
However, it is well known that pasteurization and cooking inactivate this virus.
Nevertheless, it is possible that the virus was transmitted to humans many years
ago, when bovine products were uncontrolled [35]. Once the virus was integrated
into the host genome, it is likely that transmission from person to person occurred
in the same way as its counterpart HTLV (blood, semen and breast milk) [36].
What Do we Know about BLV in Human Cancer?
The Retroviridare family includes HIV, HTLV-1 and BLV, which share structural
and functional homology. Both human viruses, HIV and HTLV, had been classified
as a group I carcinogenic virus by the International Agency for Research on Cancer
(IARC) [37]. BLV belongs to the same family as these human carcinogenic viruses.
Thus, it is possible that BLV could be carcinogenic in humans. This possibility has
not yet been studied thoroughly.
Viruses are classified into direct and indirect oncoviruses: while HTLV is a direct
oncovirus, HIV is considered an indirect oncovirus. This classification is based on
the fact that the genome of direct oncoviruses can be detected in tumor cells,
expressing proteins that cause cell transformation and immortalization. On the other
hand, indirect oncoviruses contribute to the development of cancer through chronic
inflammation and immunosuppression, usually occurring after decades of infection.
There are many similarities between BLV and HTLV-1. Both cause persistent
infections, h infect lymphocytes and are transmitted by direct contact with infected
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cells [19]. Intrauterine transmission is low because infected lymphocytes do not
pass efficiently through the placenta. In HTLV-1, breast feeding is the main route of
mother-to-child viral transmission, whereas it remains controversial as to whether
this is an important route of transmission for BLV, although it is a fact that
transmission in uterus from cow to calf is possible [23, 24, 38].
In both cases, tumor development is not related to the integration site in the host
genome [39]. The viral protein Tax plays an important role in tumorigenesis, as it
stimulates cell survival activating the transcription factor NF-κB, and also increases
the expression of anti-apoptotic proteins (such as Bcl-2) [40] and the expression of
TNF-α [41]. However, the effect of Tax is not enough for tumor development; other
factors such as mutations in the tumor-suppressor protein p53 [16] might be
necessary. Both BLV and HTLV-1 only induce leukemia or lymphoma in a low
percentage (1–5%) of the infected individuals and this occurs years after initial
infection [18, 42].
Why Do we Associate BLV with Breast Cancer?
Due to the discovery of BLV p24 and viral DNA in bovine mammary tissue,
scientists considered the possibility that BLV could be found in human in the same
tissue [43]. A first attempt to identify BLV in human breast was made by Buehring
and collaborators who analyzed 219 FFPE breast tissue samples. The viral gene tax
was detected in 44% (n = 97) of samples from human breast cancer analyzed by in
situ PCR. In 12 out of 215 samples (6%), the 24 kD viral protein was detected by
immunohistochemistry. These results suggest that, in some way, the virus could be
active because p24 is a marker of viral replication [15].
The viral gene env encodes an envelope glycoprotein, gp51, which has a major role
in the infection process [18]. In 2006, Cruz and collaborators analyzed 56 samples
from human breast cancer by immunohistochemistry for gp51. They detected this
protein in 7% of the samples (4/56) [14]. The presence of gp51 is also indicative of
viral replication.
In a retrospective study, 53 human samples of FFPE breast cancer tissue and 53
control samples of the same tissue stored at a hospital in Bogota, Colombia, were
analyzed. By conventional PCR, they were able to amplify a fragment of the viral
gene gag, which codifies for the viral capsid [44], in 35% of the breast cancer
samples and 45% of the control tissues [45]. The odds ratio, which indicates the
possibility of the disease occurring in people exposed and not exposed to BLV, did
not establish an association between BLV and breast cancer. However, they found
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that samples from older patients had a greater likelihood of being positive for BLV
sequences, similar to the findings by Buehring [35]. This is an important fact if we
consider that people exposed to the virus is supposed to occur through dairy and
meat. While growing older, the possibility of accumulating more events of exposure
through continuous consumption of these foods could be increased.
A similar analysis, performed in 2015, analyzed viral gene tax expression using in
situ PCR. The target gene was amplified in 29% of the controls, 38% of the
premalignant lesions and 59% of malignant samples. The odds ratio of the
association between the presence of BLV DNA and breast cancer was 3.07, a value
similar to that obtained for other risk factors such as hormonal exposure, number of
births and lifestyle [35].
Recently, a study conducted in Australia detected the presence of a BLV gene
before and after breast cancer development. These results showed that viral DNA
could be detected in this tissue many years before the onset of the disease. In 10
cases, it was possible to obtain enough DNA to sequence the viral LTR. The LTR
sequences were compared to a reference sequence. After comparison, authors
showed that in 6 samples the LTRs had a 100% homology with the reference
sequence and 4 had at least one substitution [46].
On the other hand, other studies show absolutely different results. These studies
disagree with the findings that imply an association between BLV and breast
cancer. In a thorough study conducted in China in 2016 on 91 breast cancer tissues
and 160 blood samples from women with a breast cancer diagnosis, it was not
possible to detect BLV transcripts or antibodies against the virus [47]. In analyzing
these results, Buehring concluded “we used in situ PCR, which requires sample
preparation, cycling times/temperatures, reaction mix composition, and a thermal
cycler different from those used for standard solution PCR and real-time PCR. It is
impossible from the information given to evaluate whether the authors’ in situ PCR
techniques were equivalent to what we used” [48]. Furthermore, the commercial
ELISA kit they used was specially intended for cattle. These kits usually are
standardized and extensively tested for the level of anti-BLV antibodies usually
found in BLV-infected cattle, which is much higher than in humans [28, 49].
Another study, performed by Gillet and collaborators, analyzed the complete
genome of 51 breast tumors obtained from the NCBI database (dbGaP, NCBI
database of genotype and phenotype). In this case, they evaluated the presence of
BLV sequences by aligning the retrieved sequences with different BLV strains,
using human genomic sequences as the positive control. They used the “very
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sensitive” option of Bowtie2 to maximize likelihood of viral detection, and created
“in silico” divergent sequences. They had no positive results, no matter the
technology used for analysis [50].
Recently, a case control study of women in Texas supports the results found in
previous studies showing an association of BLV DNA with breast cancer. They
detected a fragment of the tax gene in 20% of benign, 34% of pre-malignant, and
57% of malignant tissues. Moreover, they assessed HPV presence in these samples.
Their conclusion was that there is no association of oncogenic strains of HPV with
either breast cancer development or with BLV presence [51].
Will there Be Solid Proof that BLV Is Associated with
Breast Cancer?
The development of cancer is the result of complex interactions between genetic
and epigenetic factors. Direct oncogenic viruses contribute to the development or
progression of certain cancers favoring the accumulation of mutations or preventing
tumor cell removal by blocking the expression of apoptotic genes. In addition to
direct mechanisms, chronic viral infections create an inflammatory environment
that indirectly contributes to tumor formation. With all this information in mind, it
might be possible that BLV plays a role in human breast cancer given that it
produces persistent infections and has functional and structural similarities with
HTLV-1, a human direct oncovirus [18, 27, 52].
Detecting the viral DNA in breast cancer tissue is only a beginning link to any
association between BLV and this type of cancer. The human genome typically
contains thousands of endogenous retroviruses, many of which are derived from
retroviruses that circulated millions of years ago. This is why in a first instance it
should be discarded that the detected BLV sequences come from that source. To
establish a causal relationship there must be prospective studies demonstrating that
viral infection precedes tumor development. In this case, there is only one
prospective study carried out in Australia that should be validated with other
research [46]. Another future perspective is to identify the precise route of virus
transmission to humans and to determine how many infected individuals develop
cancer.
In any case in which a virus is associated with cancer development (such as HTLV-
1, HPV, EBV or hepatitis C virus), viral presence should be accompanied by other
factors inherent to the individual and the environment which stimulates cellular
transformation [53]. One example is EBV, whose prevalence worldwide is around
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90%. However, the incidence of Burkitt’s lymphoma, which is associated with EBV
infection, is higher in Africa. This could be due to environmental or genetic factors
that make people in Africa more susceptible to the development of this cancer [54].
It would be interesting to evaluate the contribution of each of these factors to the
development or progression of breast cancer in association with BLV. This may
explain why not all people exposed to this virus develop cancer.
In 1965, Sir Austin Bradford Hill described criteria to evaluate causal association
between environmental and occupational exposures and the development of certain
diseases. These nine criteria are also used to evaluate a virus’ oncogenic potential.
Due to the complexity of cancer (where viral, host and environmental factors are
involved) it is not necessary to fulfill all the criteria in order to associate a virus
with a cancer.
Hill’s criteria includes: consistence of the observation; strength of the association;
specificity; temporality; biological gradient (if the incidence of the disease
increases with the exposition), biological feasibility; coherence of the association;
experimental evidence and analogy of the exposition with other well-known cause
of the disease [55].
In the case of BLV, several criteria, but not all, are met, such as strength of
association and consistency: some parts of the virus have been detected in different
populations and by different methodologies [14, 15, 35, 45, 46]. The temporality
was proven by Buehring and her Australian counterpart: they detected viral
sequence in mammary tissue many years before tumor development. Moreover, in
some cases they could not detect BLV sequence in the first sample taken from the
patient but were able to identify viral transcripts in tumor samples from the same
individual after several years [46]. These results might support the idea of a causal
relationship between BLV and the further development of breast cancer.
Lastly, following analogy criteria, BLV and HTLV structural and functional
similarity can let scientists consider the possibility that BLV could affect humans in
some way. BLV and HTLV are both members of the Deltaretrovirus genus,
characterized by the presence of a unique sequence called pX region located
between the env gene and the 3’LTR. This sequence encodes regulatory proteins,
like Tax and Rex that are not present in other retroviruses [16]. These similarities
support the hypothesis that continuous contact between BLV and humans could lead
to a virus adaptation to this new host.
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Many studies in this field have been performed by different groups, with dissimilar
conclusions. The fact that some researchers could not find the virus in breast cancer
patients could be related to the methodology used and the population in which the
study was conducted.
Zhang and collaborators developed their research in different regions of China. It is
known that milk consumption in the Chinese population is four times lower than in
Argentina and almost 10 times lower than in industrialized countries like Australia,
New Zeland, or the United States [56]. There is a correlation between bovine milk
and meat consumption and breast cancer. Countries with high consumption of these
products have a higher prevalence of breast cancer than countries like China or
India that consume fewer products derived from cattle. Moreover, women with
lactose intolerance have a lower prevalence of breast cancer than other women and
other family members, reinforcing the importance of considering milk consumption
habits when analyzing the population in a study [57].
Many facts suggest that it is unlikely to detect retroviral sequences by next
generation sequencing techniques. Despite the enormous amount of data that can be
obtained through high-throughput shotgun sequencing, viral DNA in a typical
clinical sample usually represents a very low proportion of the host genome [58].
Another possibility could be that the samples analyzed had a low number of
infected cells, or that, despite being infected, the level of integrated retrovirus was
too low. More research in human database needs to be done. Due to the quantitative
disproportion between viral and host genomic material, previous enrichment of the
target by in-solution or solid-surface hybridization could be a good approach [59].
In addition, it cannot be assumed that viruses associated with human breast cancer,
like MMTV, HPV or BLV, exert their action by continuously expressing their
proteins [58].
On the other hand, BLV sequences were detected in tissue control samples that
came from reductive surgeries. The authors consider that these tissues could be in
early stages of a neoplasia that might be evident clinically many years later [35,
46]. This is consistent with viral action in cattle, where it maintains a low
transcriptional rate to escape from the immune system and provokes lymphoma
many years after initial infection [18]. As previously described, the BLV oncogenic
effect is not related with the expression of oncoproteins or its place of insertion in
the host genome. The viral protein Tax has a major role in oncogenesis, affecting
some DNA damage repair mechanisms that contribute to an accumulation of
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mutations [16]. This could explain why, both in cattle and human, tumors appear
many years after initial contact with the virus.
Conclusions
Regarding the arguments presented in this review, there is not a consensus about the
possible relationship between BLV and human breast cancer. To end these
controversies, it is essential to isolate an infective viral particle from a breast tumor,
from human breast milk, or from meat for human consumption.
Identification of a link between BLV and breast cancer pathogenesis would improve
preventive strategies were a link proven [60]. Confirming that BLV is related to
human breast cancer would be of great importance as it is a worldwide-distributed
virus in cattle and there are several instances in which humans can be exposed.
More research has to be done to confirm if BLV is associated with breast cancer in
humans. If, indeed, there is a relation between BLV and cancer, then it will be
peremptory for governments to design eradication plans, mostly to reassure the
population. If this relation does not exist, then it will be necessary to understand
why fragments of the BLV genome can be detected in human tissue.
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